- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03080597
PrEP for HBCUs (Study 2) (PrEP for HBCUs)
Study Overview
Detailed Description
The following is only pertaining to study 2, HBCUs. PrEP Smart (study 1) is not included in this record.
The investigators' overall goals are to target (a) pre-exposure prophylaxis (PrEP) uptake by addressing access and acceptability and (b) PrEP adherence among Historically Black Colleges and Universities (HBCU) students.
Aim 1/Study 1. Investigate uptake of PrEP services on HBCU campuses. Making PrEP available on HBCU campuses may address uptake by increasing (a) accessibility by allowing students to gain access to tenofovir disproxil fumarate/emtricitabine (TDF/FTC) without having to leave campus and (b) acceptability by providing trained practitioners and student advocates on campus to educate students on the benefits of PrEP. Aim 1a will target PrEP uptake at HBCUs at the healthcare systems level. The investigators will identify Student health centers (SHC) practitioners on 6 HBCUs (North Carolina Central, St. Augustine's, Fayetteville State University, Shaw, North Carolina A&T, and Bennett College). After a comprehensive SHC needs assessment, the investigators will train practitioners on eligibility for PrEP, pre-initiation counseling, and prescribing in partnership with the North Carolina AIDS Education and Training Center (NC AETC). The investigators will also engage key student organizations on campus and train motivated student advocates for the dissemination of information about PrEP on campus. Aim 1b will target PrEP uptake at the individual level. First, the investigators will collect data on all clinical encounters for PrEP at participating SHCs during the study period. Data will be collected on the basic demographics and risk factors necessitating the initiation of PrEP. The investigators will also collect data on PrEP initiations, as well as the number of prescriptions written in follow up during the period of study. To better understand PrEP behaviors on campus, the investigators will ask students initiated on PrEP to take a brief, anonymous questionnaire on relevant topics including: (1) PrEP awareness, (2) Motivation for initiating PrEP, (3) Perceived stigma of HIV and HIV associated risk factors on campus, and (4) Perceptions of confidentiality regarding seeking PrEP services on campus. The investigators anticipate enrolling approximately 250 students for this portion of the study.
Aim 2/Study 2. Adapt a smartphone-based contingency management (CM) application ("app") intervention designed to improve PrEP adherence. CM is a behavioral intervention that involves the systematic use of reinforcement dependent on the occurrence of a predefined behavior. CM improves adherence to antiretroviral therapy (ART) and post-exposure prophylaxis (PEP), and is currently being developed by the investigative team for PrEP. Since the cost of traditional CM interventions may be prohibitive in practice, the investigators will adapt this intervention using a lower cost reinforcement procedure and therefore improve the scalability of this adherence intervention. In a sample of young men who have sex with men (YMSM) prescribed PrEP (n = 20) over an 8 week period, Aim 2a will assess app interaction to address feasibility, Aim 2b will assess acceptability via self-report quantitative ratings and qualitative interviewing, Aim 2c will assess the validity of daily camera-based medication ingestion assessment via the app to validate medication adherence against blood tests to detect PrEP, and Aim 2d will assess barriers to adherence via app-based daily assessments following missed doses.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Enrolled as a student in a Historically Black College or University, OR identify as Black/African American
- Male
- Self-report having sex with men in the past 6 months
- 18-30 years of age
- English-speaking
- Currently prescribed PrEP (Truvada) for HIV prevention
- Participant has an Android (using v5.x.x or lollipop) or iOS (v6.0) smartphone
Exclusion Criteria:
- History of a chronic/significant medical or psychiatric condition that will interfere with study participation
- Unable to attend sessions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smartphone app condition
English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called "PrEP Smart".
|
English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called "PrEP Smart".an
application on their smart phones called "PrEP Smart".
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility as measured by the number of times per day that subjects initiate an interaction with PrEP Smart
Time Frame: 8 weeks
|
As measured by the number of times per day that subjects initiate an interaction with PrEP Smart
|
8 weeks
|
Feasibility as measured by the number of times per day that subjects respond to a PrEP Smart prompt
Time Frame: 8 weeks
|
As measured by the number of times per day that subjects respond to a PrEP Smart prompt
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability will be assessed during the final laboratory visit with an open ended qualitative interview assessing overall feedback
Time Frame: 8 weeks
|
Will be assessed during the final laboratory visit with an open ended qualitative interview assessing overall feedback.
|
8 weeks
|
Acceptability will be assessed by feedback specific to each of the six individual PrEP Smart features
Time Frame: 8 weeks
|
Will be assessed by feedback specific to each of the six individual PrEP Smart features.
|
8 weeks
|
Adherence will be assessed by the number of times that PrEP was taken daily over the 8 week period and the number of times that it was taken outside of a one hour window in which it was prescribed
Time Frame: 8 weeks
|
Will be assessed by the number of times that PrEP was taken daily over the 8 week period and the number of times that it was taken outside of a one hour window in which it was prescribed.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John T Mitchell, Ph.D., Study Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00076107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on At Risk for HIV
-
Duke UniversityIntelligent Automation, Inc.Completed
-
Public Health Management CorporationCenters for Disease Control and PreventionCompletedBisexually-active Men | at Risk for HIVUnited States
-
Sebela Women's Health Inc.Synteract, Inc.Active, not recruitingWomen at Risk for PregnancyUnited States
-
Sebela Women's Health Inc.Synteract, Inc.Active, not recruitingWomen at Risk for PregnancyUnited States
-
University of California, San DiegoNational Institute of Mental Health (NIMH); Indian Council of Medical Research and other collaboratorsCompletedBehavioral Risk for HIVIndia
-
Sebela Women's Health Inc.PRA Health SciencesNot yet recruitingContraception | Women at Risk for PregnancyUnited States
-
Boston Children's HospitalCompletedCar Seat Transition for At-risk InfantsUnited States
-
University of FloridaJohns Hopkins University; National Institutes of Health (NIH)CompletedYouths At-risk for Drug Use/AbuseUnited States
-
WestatChildren's Bureau - Administration for Children and FamiliesCompletedIn Foster Care | At Risk for Foster
-
University of Southern CaliforniaCompleted
Clinical Trials on PrEP Smart app
-
Duke UniversityIntelligent Automation, Inc.Completed
-
Columbia UniversityRecruiting
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical CenterRecruitingPost Traumatic Stress DisorderUnited States
-
Duke UniversityCompletedSickle Cell DiseaseUnited States
-
Duke UniversityRecruiting
-
Wuerzburg University Hospitalaycan Medical Systems LTD, Innere Aumuehlstr. 5, 97076 Wuerzburg , GermanyActive, not recruitingObesity | Bariatric Surgery CandidateGermany
-
Environment and Health Group, Inc.Completed
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Peking University People's HospitalPeking UniversityUnknownKnee Osteoarthritis | Arthroplasty, Replacement, Knee
-
Harvard School of Dental MedicineNot yet recruitingDiabetes Mellitus | Periodontal Diseases